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Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) and
cerebral dopamine neurotrophic factor (CDNF) promote the survival of midbrain
dopamine neurons in animal models of Parkinson’s disease (PD). However, little is known
about endogenous concentrations of MANF and CDNF in human PD patients, and
their relation to PD pathogenesis. Our main objective was to study whether circulating
concentrations of MANF and CDNF differ between PD patients and controls, and if
they correlate with clinical parameters. Levels of circulating CDNF were studied for the
first time.
Methods: MANF and CDNF levels were measured from serum samples of 34 PD
patients and 35 controls using validated in-lab-designed enzyme-linked immunosorbent
assay (ELISAs). MANF and CDNF mRNA levels in whole blood samples of 60
PD patients and 30 controls were measured by quantitative real time polymerase
chain reaction (qRT-PCR). MANF concentrations in different blood cell types were
measured by ELISA.
Results: Circulating MANF concentrations were significantly higher in PD patients
compared to controls (P < 0.001) and were positively correlated with Beck Depression
Inventory (BDI) depression rating. MANF protein was present in blood cells, however,
MANF mRNA levels in the blood did not differ between PD patients and controls
(P = 0.44). The mean concentration of serum CDNF was 33 pg/ml in the controls. CDNF
levels were not altered in PD patients (P = 0.25).
Conclusion: MANF but not CDNF level was increased in the blood of PD patients. It
would be interesting to examine the blood level of MANF from early stage PD patients
in future studies to test whether MANF can be used as a clinical marker of PD.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder leading
to severe motor impairment. Loss of midbrain dopamine neurons
and accumulation of Lewy bodies are typical pathological features
in the brain of PD patients. It has been estimated that by
the time PD has been clinically diagnosed, 30% of dopamine
neurons in the Substantia nigra have been lost (Cheng et al.,
2010). Pathological changes are not restricted to the brain, and
Lewy bodies are also found in the peripheral nervous system
(Del Tredici and Braak, 2016; Poewe et al., 2017). Non-motor
symptoms of PD, including sleep disorders, olfactory dysfunction
and autonomic dysfunction can be present years before the
clinical onset of motor symptoms. Cognitive impairment and
depression are also characteristics of PD. Although the current
treatment for PD is symptomatic, novel treatments are being
investigated for slowing down or reversing the pathogenesis
(Poewe et al., 2017).
Mesencephalic astrocyte-derived neurotrophic factor
(MANF) and cerebral dopamine neurotrophic factor (CDNF)
are endoplasmic reticulum (ER)-localized, secreted proteins
with neuroprotective and neurorestorative activities (Lindahl
et al., 2017). Originally, MANF was discovered based on its
survival-promoting activity on cultured dopamine neurons
(Petrova et al., 2003); CDNF was later identified as its paralog
(Lindholm et al., 2007). Studies in Drosophila and zebrafish
indicate that MANF is important for the development of the
dopamine system, since its removal decreased dopamine levels
and altered the morphology and number of dopamine neurons
(Palgi et al., 2009; Chen et al., 2012). The neuroprotective effects
of CDNF and MANF have been studied in animal models of
PD. For example, it has been shown that delivery of CDNF
protein to the brain parenchyma protected dopamine neurons
in rat midbrains against 6-hydroxydopamine (6-OHDA) and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
degeneration, and promoted functional recovery (Lindholm
et al., 2007; Airavaara et al., 2012). The neuroprotective effect
of CDNF has also been demonstrated using adeno-associated
virus mediated gene delivery in rat 6-OHDA models of PD (Back
et al., 2013; Ren et al., 2013). In marmoset monkeys, CDNF
promoted dopamine transporter activity in a 6-OHDA model of
PD (Garea-Rodriguez et al., 2016). CDNF is currently in phase
I-II clinical trials on human PD patients (ClinicalTrials.gov
identifier: NCT03295786; Huttunen and Saarma, 2019). Similar
to CDNF, MANF has also demonstrated protective effects on
midbrain dopamine neurons in rodent 6-OHDA and MPTP
models of PD (Voutilainen et al., 2009; Hao et al., 2017;
Liu et al., 2018).
Since MANF and CDNF have protective properties for
dopamine neurons, they are potential therapeutic proteins
for PD. However, less is known about their association with
human PD pathophysiology. Here our aim was to study the
possible association of circulating MANF and CDNF with
human PD pathogenesis. We measured serum MANF and
CDNF concentrations from PD patients and controls, and




Two populations were included in the study. Blood samples
for enzyme-linked immunosorbent assay (ELISA) analyses
were collected from 34 patients with PD and 35 controls
(Table 1). PD patients had a mean age of 74.4 ± 8.6 years
and controls 75.3 ± 8.2 years. Mean duration of PD was
6.4 ± 6.8 years. Whole blood samples for total RNA isolation
and quantitative real time polymerase chain reaction (qRT-
PCR) analysis were collected from 60 PD patients and 30
controls (Table 1). The mean age of the PD patients and
healthy controls were 73.2 ± 8.0 and 73.0 ± 7.9 years,
respectively. The mean duration of PD was 7.1 ± 6.8 years.
The study was approved by the Research Ethics Committee
of the University of Tartu, and all subjects provided written
informed consent.
Clinical Assessment
Only patients who fulfilled the Queen Square Brain Bank
Criteria for PD (Gibb and Lees, 1988; Poewe et al., 2017)
were recruited. Patients with PD underwent medical assessment,
which included clinical history, comorbid diseases, toxins in
history, and medication use. The disease severity was staged
according to the Hoehn and Yahr (H&Y) scale (Hoehn and
Yahr, 1967), and the disability was assessed with the Schwab
and England Activities of Daily Living (SE-ADL) scale (Schwab
et al., 1969). The severity of the PD symptoms was identified
by using the Movement Disorders Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS), as a rule rated in the ON-
stage of the disease (Goetz et al., 2008). Cognitive function
was assessed using the Mini Mental State Examination (MMSE)
TABLE 1 | Demographic and clinical data on the study populations included in
ELISA or qRT-PCR analysis.










Age (years) 74.4; 48–87 75.3; 58–90 73.2; 48–85 73.0; 58–85
Female:Male 18:16 19:16 34:26 15:15
Duration of PD
(years)
6.4; 1–35 7.1; 0.7–35
MDS-UPDRS
(total)
76.7; 26–167 71.3; 22–167
H&Y 2.9; 1.5–5 2.8; 1–5
SE-ADL 75.6; 40–100 76.4; 40–100
MMSE 27; 20–30 27.2; 18–30
BDI 15.2; 2–32 14.8; 0–32
SS12 5.7; 0–11 5.8; 0–11
BDI, Beck depression inventory; ELISA, enzyme-linked immunosorbent assay;
H&Y, Hoehn and Yahr staging; MDS-UPDRS, movement disorder society-unified
Parkinson’s disease rating scale; MMSE, mini mental state examination; qRT-PCR,
quantitative reverse transcription-polymerase chain reaction; SE-ADL, Schwab–
England activities of daily living scale; SS12, sniffing sticks olfactory test.
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(Folstein et al., 1975). Depression was rated with the Beck
Depression Inventory scoring (Beck et al., 1961) based on 21
questions with ratings from 0 to 3 to measure severity of
depression. A score of 18 points signifies depression in PD
patients (Silberman et al., 2006; Tumas et al., 2008). Olfactory
performance was assessed with the Sniffin’ Sticks Olfactory
test (SS-12) (Hummel et al., 1997). Current PD medications
of the patients involved in the ELISA measurements are
provided in Supplementary Table S1. Comorbidities and other
physiological or medical conditions of the PD patients are listed
in Supplementary Table S2.
Controls
The control group was formed from healthy volunteers
without any current neurological condition, and individuals
who visited outpatient or inpatient clinics of the Department
of Neurology and Neurosurgery of Tartu University Hospital
without any current neurodegenerative disease but because of
other neurological conditions.
Serum Samples
Blood samples were collected to BD Vacutainer R©tubes and
allowed to clot at room temperature. Serum was separated by
centrifugation at 1300× g for 10 min at room temperature (RT),
and stored at−80◦C until analysis.
Human MANF ELISA
The development and validation of human MANF ELISA for
the measurement of MANF in serum has been described earlier
(Galli et al., 2016). The dynamic range of MANF ELISA is 62.5–
2000 pg/ml, and its sensitivity is 45 pg/ml. Human MANF ELISA
does not recognize recombinant human CDNF. For MANF
quantitation, serum samples were diluted at 1:20 in blocking
buffer [1% casein in phosphate buffered saline, 0.05% Tween-20
(PBST)]. To block interference caused by heterophilic antibodies
(HAs), Immunoglobulin Inhibiting Reagent (IIR; BioIVT) was
added to the serum samples at concentration of 500 mg/l.
Diluted samples and standards were applied to 96-well plates
coated with goat anti-human MANF antibody (AF3748, R&D
Systems), and incubated overnight at +4◦C in agitation. After
washing with PBST, bound MANF on the plates was detected
using horseradish peroxidase (HRP)-conjugated mouse anti-
human MANF antibody (4E12, Icosagen) and DuoSet ELISA
Development System (R&D Systems). Absorbance was read at
450 nm and 540 nm using VICTOR3 plate reader.
Human CDNF ELISA
The development of human pAb CDNF ELISA has been
described (Back et al., 2013). Sensitivity of the CDNF ELISA is
6.2 pg/ml (determined as the mean+ 3 standard deviations (SDs)
of 10 blank samples) and the quantitation range 7.8–500 pg/ml
(Supplementary Table S3). The antibodies used in CDNF ELISA
were goat anti-hCDNF (1 µg/ml, R&D Systems) for coating, and
rabbit anti-CDNF (0.1 µg/ml, Lindholm et al., 2007) followed by
HRP-conjugated donkey anti-rabbit (1:2000, GE Healthcare) for
detection. The mean intra- and inter-assay variations (analyzed at
three different concentration levels) are 9.3± 2.5 and 9.7± 1.5%
CV, respectively. For testing the blockage of HA-interference, we
added IIR to serum samples at concentration of 100 and 500 mg/l,
and monitored the background with a control ELISA (cELISA)
as described (Galli et al., 2016). The cELISA was run exactly as
the CDNF ELISA; the only difference was a coating antibody,
which was goat anti-hMANF (1 µg/ml, R&D Systems), opposed
to goat anti-hCDNF used in the CDNF ELISA. Cross-reactivity of
cELISA for neither recombinant CDNF nor MANF was verified
at a concentration of 2 ng/ml. Linearity of dilution and recovery
of spiked CDNF in serum was tested in the presence of IIR.
Fractionation of Blood Cells and
Quantitation of MANF
For fractionation, we pooled 10 subjects’ blood obtained from
the Finnish Red Cross (license 43/2017). A total of 50 ml citrate-
blood was centrifuged at 150× g for 20 min at room temperature
with no brake applied. The platelet-rich plasma was transferred
into a new tube without disturbing the buffy coat, and HEP
buffer, pH7.4, (140 mM NaCl, 5 mM EDTA, 3.8 mM HEPES,
2.7 mM KCl) was added at a 1:1 ratio. The sample was mixed
gently to prevent platelet activation and centrifuged at 100 × g
for 15–20 min at RT to pellet contaminating red and white
blood cells (RBCs and WBCs). The remaining supernatant was
centrifuged at 800 × g for 20 min at RT to pellet platelets.
Isolated platelets were rinsed twice with 1 mM EDTA in PBS (pH
7.4) and homogenized in 400 µl of lysis buffer (20 mM Tris–
HCl, pH 8.2, 137 mM NaCl, 1% NP40, 10% glycerol, 0.5 mM
Na3VO4, Complete Mini protease inhibitor cocktail (Roche)).
After 20 min incubation on ice, the sample was centrifuged at
12,000 × g for 20 min at + 4◦C, and the supernatant was stored
at−80◦C until analysis.
WBCs were collected by isolating the buffy coat of the initial
centrifugation. Contaminating RBCs were lysed by the addition
of 0.5 ml of eBioscienceTM RBC Lysis Buffer (Invitrogen)
and incubated for 15 min at RT. WBCs were pelleted by
centrifugation at 500 × g for 5 min at RT. The supernatant was
decanted, and the pellet was carefully resuspended in cold PBS
and centrifuged again. The washed pellet was homogenized in
400 µl of lysis buffer.
For RBC isolation, the top layer contaminated with buffy coats
was removed and 400 µl of the RBC layer was collected. 8 ml of
PBS was added to the RBC layer and centrifuged at 500 × g for
10 min at RT. The supernatant was removed, and the washing was
repeated two more times. The pellet of RBCs was homogenized in
800 µl of lysis buffer.
Mesencephalic astrocyte-derived neurotrophic factor in the
homogenates was quantitated by hMANF ELISA and the result
normalized to the total protein concentration measured by DC
Protein Assay (Bio-Rad Laboratories).
Western Blotting
Protein samples derived from fractionated blood cells were
reduced by boiling with β-mercaptoethanol, separated on 4–
15% SDS-PAGE (MiniProtean R©TGXTM, Bio-Rad; 50 µg/lane)
and blotted on a nitrocellulose membrane. Proteins were stained
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with Ponceau S (0.1% in 5% acetic acid) after which MANF
was detected with rabbit anti-MANF (1 µg/ml, Icosagen)
followed by HRP-conjugated secondary antibody against rabbit
IgG and enhanced chemiluminescence (ECL) Western Blotting
Substrate kit (Pierce).
RNA Isolation and Real-Time
Quantitative PCR
Whole blood samples were collected into Tempus Blood RNA
tubes (Applied Biosystems) and frozen at −80◦C. Total RNA
was isolated using Tempus Spin RNAS isolation kit (Applied
Biosystems). 200 ng of RNA was used for cDNA synthesis
using High Capacity cDNA Reverse Transcription Kit with
RNase Inhibitor (Applied Biosystems). cDNA was used as a
template for TaqMan R©qRT-PCR analysis in the ABI Prism
7900HT Sequence Detection System (Applied Biosystems, Foster
City, CA, United States). TaqMan R©Gene Expression Master Mix
and FAM labeled TaqMan (Applied Biosystems) gene assays
were used to detect the mRNA expression level of the gene of
interest and of actin as a reference gene. The TaqMan probes
used were: Hs00180640_m1 (MANF), Hs00418490_m1 (CDNF),
and Hs01060665_g1 (ActB). Reactions were carried out in four
replicates. Data was analyzed using the 2(-Delta Delta C(T))
method, where the gene expression levels were normalized to the
level of the actin beta housekeeping gene.
Statistical Analysis
The distributions of MANF and CDNF concentrations were
skewed (Shapiro–Wilk test, P < 0.05 for both), thus non-
parametric statistical tests were carried out to analyze serum data.
Bivariate correlations were analyzed with Spearman’s correlation
test. Kruskal–Wallis, along with Tukey HSD post hoc test, and
Mann–Whitney U-tests were used to compare MANF and CDNF
serum levels in different groups. qRT-PCR data was analyzed
with the parametric unpaired t-test. P ≤ 0.05 was considered
statistically significant for all tests. Statistical analyses were
performed using Software Package for Social Science (SPSS) v.
21.0. All results are expressed as mean± SD.
RESULTS
Serum MANF Levels Are Higher in PD
Patients Compared to Controls
The average serum MANF concentration was twice as high in PD
patients compared to their age-matched controls (Figure 1A).
Serum MANF concentration was 10.2 ± 8.6 ng/ml (median:
6.7 ng/ml, n = 34) in PD patients and 5.0 ± 4.0 ng/ml (median:
4.3 ng/ml, n = 35) in the control group (P < 0.001). The
difference in MANF serum concentration between the groups
was 5.2 ng/ml, which represent a 105% increase.
Positive Correlation Between MANF
Concentrations and BDI Scoring
Serum MANF level was not dependent on duration or severity
of PD (Table 2), or used medication (Supplementary Table S1).
However, a positive correlation was found between serum MANF
concentration with BDI scoring (rs = 0.42; P = 0.02; Figure 1B).
In PD patients who scored 18 or more points the average
serum MANF level was 14.7 ± 12.8 ng/ml (n = 10), while in
FIGURE 1 | (A) Increased levels of circulating MANF (Mann–Whitney U-test, P < 0.001) in PD patients versus controls as measured by in-lab-designed ELISA.
(B) Positive correlation between MANF concentration and Beck Depression Inventory (BDI) score in PD patients (rs = 0.42; P = 0.02). (C) The average level of serum
MANF was higher in PD patients scoring 18 or more BDI points than in patients with scores of 17 or less (Mann–Whitney U-test, P = 0.031). (D) MANF mRNA levels
do not differ between the blood of PD patients and controls (t-test, P = 0.44).
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patients scoring 2–17 points the average MANF concentration
was 7.1± 4.2 ng/ml (n = 21, P = 0.031; Figure 1C).
MANF mRNA Levels in Blood Cells Do
Not Differ Between PD Patients and
Controls
It has been reported that MANF mRNA is expressed in
the peripheral WBCs (Wang J. et al., 2014). Thus, it is
possible that circulating MANF is derived from blood cells.
We used ELISA to quantitate MANF levels in different types
of blood cells isolated from healthy human donors. MANF
levels in RBCs, WBCs, and platelets in a pooled blood
sample were 0.1, 79.5, and 358.8 ng/mg of total protein,
respectively (Supplementary Figure S1A). In agreement, MANF
was detected in platelets but not in RBCs by Western blot
(Supplementary Figure S1B).
Next, we used qRT-PCR analysis to measure MANF mRNA
levels in whole blood derived from the PD patients and controls.
However, MANF transcripts were not elevated in the blood of PD
patients compared to controls (P = 0.44; Figure 1D).
CDNF Is Present in Blood Circulation at
Low pg/ml-Levels
We have previously found a significant interference in our in-
lab-designed hMANF ELISA by HAs present in human blood
circulation (Galli et al., 2016). Similar interference was observed
in the hCDNF ELISA as analyzed by a cELISA. The cELISA
was constructed on an antibody pair derived from the same
host species as the antibodies in the original ELISA, but without
reactivity for either recombinant CDNF or MANF. Addition of
IIR to the serum samples decreased the background detected
by the cELISA. The best blockage of background caused by
HA was obtained with 1:4 serum dilution and 500 mg/l IIR
when analyzed on the hCDNF ELISA (Supplementary Table S4).
TABLE 2 | Correlations between serum MANF and clinical variables in PD patients.
Variable n Spearman’s Rho P-value
Age 34 −0.14 0.45
Duration of PD 34 0.10 0.58
MDS-UPDRS, total score 34 −0.13 0.48
MDS-UPDRS, I 34 0.05 0.79
MDS-UPDRS, II 34 −0.09 0.64
MDS-UPDRS, III 34 −0.21 0.24
MDS-UPDRS, IV 34 0.33 0.06
H&Y 34 −0.07 0.70
SE-ADL 34 0.01 0.94
MMSE 34 0.26 0.15
SS12 32 −0.25 0.17
PDQ39 32 0.25 0.17
BDI 31 0.42 0.02∗
Significant values (P ≤ 0.05) are marked with ∗. BDI, Beck depression inventory;
H&Y, Hoehn and Yahr staging; MDS-UPDRS, movement disorder society-unified
Parkinson’s disease rating scale; MMSE, mini mental state examination; SE-ADL,
Schwab–England activities of daily living scale; SS12, sniffing sticks olfactory test.
The recovery of recombinant CDNF added at concentrations of
50, 100, or 250 pg/ml to sera diluted at 1:4 and supplemented
with 500 mg/l IIR was 76.6 ± 3.3% (range 72.0–82.8%, n = 7).
Linearity of dilution of endogenous CDNF in human sera
was 95.5 ± 12.1% (n = 3 sera in 4 sequential dilutions,
Supplementary Table S5).
In general, CDNF levels in serum were much lower
than those of MANF. The range of calculated serum CDNF
concentrations in the study population was 4.3–134.4 pg/ml.
As the lower limit of detection (LLOD) of our hCDNF
ELISA is 6.2 pg/ml, and the sera need to be diluted
1:4 for optimal background control, the minimal CDNF
concentration that can reliably be distinguished from the
blank is 24.8 pg/ml.
Circulating CDNF Levels Unaltered in PD
Patients Compared to Controls
Cerebral dopamine neurotrophic factor (CDNF) concentrations
in 7 (21%) samples form the PD and 6 (17%) samples from
the control group fell below the LLOD of our hCDNF ELISA.
We approached the data analysis by three simple methods
used for dealing with samples under LLOD (Helsel, 1990): (1)
including all sample values; (2) replacing the sample values
below LLOD by 0; and (3) replacing the sample values below
LLOD by half of the LLOD (i.e., 12.4 pg/ml), which can be
considered as a rough mean value of the samples that fall
below the detection limit. All the three methods gave similar
results indicating that serum CDNF levels in PD patients
and controls do not significantly differ in the current study
population. P-values for each of the analysis methods were
following: (1) 0.25, (2) 0.28, and (3) 0.28. In the Figure 2A
we show the values also below the LLOD for not causing
an artificial skew in the distribution. However, all values
below LLOD should be taken with a level of uncertainty.
When all sample values were included in the calculations, the
average serum CDNF concentration in the PD patients was
40.3 ± 23.5 pg/ml (median: 38.1 pg/ml, n = 34), and in
the controls it was 33.3 ± 12.9 pg/ml (median: 32.5 pg/ml,
n = 35; Figure 2A).
MANF and CDNF concentrations correlated positively in the
sera from the PD patients (rs = 0.41, P = 0.016, n = 34, Figure 2B)
but not in those from the controls (rs = 0.18, P = 0.31, n = 35).
CDNF mRNA Levels Increased in the
Blood of PD Patients
Using qRT-PCR we observed that CDNF gene expression was
upregulated in whole blood samples of PD patients by 26% as
compared to controls (P = 0.015; Figure 2C).
DISCUSSION
Since MANF and CDNF promote the survival of brain dopamine
neurons in animal models of PD (Lindholm et al., 2007;
Voutilainen et al., 2009; Airavaara et al., 2012; Back et al., 2013;
Ren et al., 2013; Garea-Rodriguez et al., 2016; Hao et al., 2017; Liu
et al., 2018), we wanted to study whether their endogenous levels
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FIGURE 2 | (A) Similar levels of serum CDNF in PD patients and controls as
measured by in-lab-designed hCDNF ELISA (Mann–Whitney U-test, P = 0.25).
LLOD; lower limit of detection when samples are diluted 1:4. (B) Positive
correlation of MANF and CDNF levels in the sera of PD patients (rs = 0.41,
P = 0.016). (C) Increased levels of CDNF mRNA in the blood of PD patients
compared to controls (t-test, P = 0.015).
are altered in human subjects with PD, which would indicate
a possible contribution to the disease mechanism. Serum was
chosen for the study since its collection is minimally invasive and
endogenous levels of circulating MANF and CDNF in human PD
have not been addressed before.
The average concentration of circulating MANF was roughly
twice as high in the group of PD patients as in the controls.
MANF levels did not depend on the duration or progression
of PD, or on used medication. However, we found a positive
correlation with BDI scoring, which is used to measure severity
of depression (Beck et al., 1961). Depression is a common non-
motor symptom of PD, which negatively affects the quality of
life (Poewe et al., 2017). Depression has been demonstrated
as a strongest determinant of low health-related quality of life
in persons with PD (Kadastik-Eerme et al., 2015). Compared
to patients with lower scores, the average MANF level was
significantly higher in patients classified as depressed based on
a BDI score of 18 or higher. It is unclear whether the observed
increase in MANF is directly related to depression, or whether it
reflects PD pathophysiology leading to depression. To this end, it
would be informative to analyze MANF levels in non-PD subjects
diagnosed with depression, and compare them to healthy subjects
and those with PD.
Here, we report for the first time that CDNF can be detected
in the blood circulation. The basal levels of CDNF in human
circulation are clearly lower than the levels of MANF. The
difference between MANF and CDNF levels was approximately
170-fold (i.e., 5 ng/ml vs. 0.03 ng/ml) in the control group. We
found a positive correlation between MANF and CDNF levels
in the sera of PD patients, suggesting that patients having high
MANF serum level also had higher CDNF levels. This correlation
was not observed in the control population, implying that the
release of MANF and CDNF to the blood circulation might
be related to a pathological state. However, unlike MANF, the
average levels of CDNF were not altered in subjects with PD,
as measured by ELISA. It should be noted that in 19% (13/69)
of the samples CDNF-readings remained under detection limit,
and thus, a more sensitive ELISA could give a different result to
that we report here.
A recent study shows that CDNF levels were increased in
the hippocampi of PD patient brain. Differently from CDNF,
hippocampal levels of MANF were unaltered in PD (Virachit
et al., 2019). Whether circulating and brain tissue levels of CDNF
and MANF show any correlations in PD remains to be studied.
Indeed, the origins of MANF and CDNF in serum are still
unknown. For example, brain-derived neurotrophic factor is
stored in platelets and released upon stimulation (Fujimura
et al., 2002). We found that MANF is present in high
amounts in the platelets but whether they release MANF into
the circulation is unclear. We have not detected differences
between average concentrations of MANF in human serum and
plasma (unpublished observations), suggesting that clot-forming
platelets are not the major source of serum MANF. Furthermore,
MANF mRNA levels in whole blood did not differ between PD
patients and controls, suggesting that the increased MANF in
the serum of PD patients was not derived from blood cells. In
addition, while we observed increased CDNF mRNA levels in
the blood of PD patients, circulating levels of CDNF were not
significantly changed in PD, suggesting that CDNF mRNA levels
in blood cells and the levels of circulating CDNF do not correlate.
In the rodent brain, endogenous MANF localizes mainly to
neurons, and MANF immunoreactivity has been detected in
dopamine neurons (Lindholm et al., 2008; Wang H. et al., 2014).
However, tissue expression of MANF is also widespread outside
the nervous system (Lindahl et al., 2017). In conditions of disease,
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it is possible that MANF is secreted or non-specifically released
from damaged cells or tissues. Previous studies have shown
increased circulating MANF concentrations in prediabetes and
type 2 diabetes, and in children with recent onset of type 1
diabetes (Galli et al., 2016; Wu et al., 2017). Since increased serum
MANF levels were also observed in PD patients, it is possible that
the molecular mechanisms regulating MANF concentrations are
similar both in diabetes and in PD.
Detection of the PD pathogenesis before the onset of motor
symptoms is an important step toward developing disease-
modifying therapies. Our results show that MANF serum
concentration was doubled in patients with PD compared to
age-matched controls, whereas CDNF level was not increased.
In future studies it would be interesting to examine circulating
MANF levels from early stage PD patients to test whether MANF
can be used as a clinical marker of PD.
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